Update COVID-19 in Indonesia: 927,380 confirmed infections, 26,590 deaths (19 January 2021)
19 January 2021 (closed)
USD/IDR (14,146) -6.00 -0.04%
EUR/IDR (17,335) +57.05 +0.33%
Jakarta Composite Index (6,321.86) -67.98 -1.06%
SidoMuncul Herbal, Indonesia´s largest herbal medicine producer, is expected to conduct an initial public offering (IPO) on the Indonesia Stock Exchange (IDX) in the fourth quarter of 2013. The company, established in 1951, is a fully-modernized herbal company that strives to produce and market products that support the people´s health and well-being. The company will release 20 percent of its shares on the IDX and targets to raise IDR 1.5 trillion (USD $130 million). Kresna Securities acts as underwriter for the IPO.
SidoMuncul relies on natural ingredients for its herbal products and focuses on research, science and technology in the production processes of its products. The company has equipped its factories in Semarang (Central Java) with various supporting facilities. These facilities include an ISO 17025 certified laboratory, production facilities that conform to CPOB and CPOTB good manufacturing standards in medicine, water and waste treatment facility, a holistic clinic, and an agrotourism complex.
SidoMuncul currently operates eight laboratories. The eight laboratories are Instrumentation, Microbiology, Pharmacology, Formulation, Pharmacognosy, Stability, Tissue Culture, and Chemical Analysis (ISO 17025 certified and accredited by the National Committee of Accreditation and the National Standardization Agency).